Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06054529 · ClinicalTrials.gov registry record
Spatiotemporal Dimensions of Metabolism in Autochthonous Tumors of GBM Patients
A clinical trial of Glioblastoma Multiforme, sponsored by AdventHealth Translational Research Institute.
- Active
- Registry status
- 2
- Enrollment target
- 1
- Study location
NCT06054529 is a study of Glioblastoma Multiforme that is active but no longer recruiting, run by AdventHealth Translational Research Institute. The registered enrollment target is 2 participants, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06054529, a study of Glioblastoma Multiforme, is active but no longer recruiting, sponsored by AdventHealth Translational Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn how altered metabolism in GBM causes tumor growth and resistance to drug therapy. In this pilot research study, we will dose GBM patients with a form of nicotinamide (a natural vitamin) that we can track. The nicotinamide will be converted to methyl nicotinamide (MeNAM) in the tumor. We will measure how fast the nicotinamide is converted to methyl nicotinamide. We believe that the speed of this chemical reaction in the tumor (fast versus slow) may be correlated with GBM aggressiveness
Conditions Studied
Interventions
- PROCEDURE Surgical removal of the GBM tumor
- OTHER d4-NAM infusion
Study Locations (1)
Florida
- AdventHealth Translational Research Institute - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-09-11 |
| Est. Completion | 2025-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06054529
The ClinicalTrials.gov registry entry for NCT06054529 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (98% lower). The listed sponsor is AdventHealth Translational Research Institute, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 2 interventions - of which Surgical removal of the GBM tumor is the first listed.
NCT06054529 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06054529 about?
NCT06054529 is a clinical study titled "Spatiotemporal Dimensions of Metabolism in Autochthonous Tumors of GBM Patients". To learn how altered metabolism in GBM causes tumor growth and resistance to drug therapy. In this pilot research study, we will dose GBM patients with a form of nicotinamide (a natural vitamin) that we can track. The nicotinamide will be converted to methyl nicotinamide (MeNAM) in the tumor. We wil...
What is the current status of trial NCT06054529?
This trial is currently active not recruiting. The enrollment target is 2 participants. The study started on 2023-09-11. Estimated completion is 2025-12.
What conditions does trial NCT06054529 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme.
What interventions are being tested in trial NCT06054529?
The interventions under investigation include: Surgical removal of the GBM tumor (PROCEDURE), d4-NAM infusion (OTHER).
Who is sponsoring clinical trial NCT06054529?
This trial is sponsored by AdventHealth Translational Research Institute, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06054529 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
RECRUITING · Phase 1
-
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RECRUITING · Early Phase 1
-
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
RECRUITING · Phase 1
-
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
RECRUITING · Phase 1
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.